AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
58 hedge funds and large institutions have $220M invested in AVEO Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 9 closing their positions.
321% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $1.57M
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
56% more capital invested
Capital invested by funds: $141M → $220M (+$78.7M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more funds holding
Funds holding: 49 → 58 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$12.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.95M |
| 3 |
Millennium Management
New York
|
+$2.58M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.2M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.35M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.03M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$5.65M |
| 4 |
Renaissance Technologies
New York
|
-$5.22M |
| 5 |
AC
Armistice Capital
New York
|
-$3.55M |
AVEO Hedge Fund Activity: Q3 2017 in Review
58 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2017, worth a combined $220M — up 56% from $141M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AVEO positions and 9 closed out — a net gain of 10 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $12.8M. The largest seller was Point72 Asset Management, cutting an estimated $8.35M.
- 58 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2017, up from 49 in Q2 2017.
- Funds reported $220M of AVEO Pharmaceuticals, Inc. stock for Q3 2017, up 56% quarter-over-quarter.
- 19 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2017 and 9 closed out, a net change of +10 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2017 was Polar Capital, an estimated $12.8M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2017 was Point72 Asset Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q3 2017.